Tobin Schilke, CFO at Revance Therapeutics, Inc. (RVNC), sold 37,034 shares at $31.59 ($1.2M) on 2023-03-09, disclosed to the SEC on 2023-03-09.
Open-market sale of $1.2M RVNC by CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.59 | 18,517 | $585K | 50.0% |
| 2 | $31.59 | 18,517 | $585K | 50.0% |
| Total | $31.59 avg | 37,034 | $1.2M | 100% |
| Filing → |
| RVNC | SELL | 2023-07-05 | $43K | — | Filing → |
| RVNC | SELL | 2023-06-05 | $181K | — | Filing → |
| RVNC | SELL | 2023-05-16 | $1.5M | — | Filing → |